ArticlemBio2016
Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix.
Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed, 1 synthesis or guideline pooled it, 279 citations in OpenAlex.
- Biofilm Formation on Endotracheal and Tracheostomy Tubing: A Systematic Review and Meta-Analysis of Culture Data and Sampling Method.MicrobiologyOpen · 2025Pooled it
- Bacterial-fungal interactions: connections and consequences.Essays in biochemistry · 2026Review
- Lactic acid bacteria-derived biosurfactants: emerging strategies for biofilm control, virulence attenuation, and food safety.World journal of microbiology & biotechnology · 2026Review
- From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression.MicrobiologyOpen · 2026Review
- Interkingdom Biofilms in Chronic Wounds: The Collaboration ofAntibiotics (Basel, Switzerland) · 2026Article
- The metabolic trap:Journal of medical microbiology · 2026Article
- Article
- Model-dependent efficacy of sequential phage-antibiotic-antifungal therapy against dual-species biofilms.Biofilm · 2026Article
- Copper-driven mutualism ofMicrobiology (Reading, England) · 2026Article
- Article
- Secreted factors ofApplied and environmental microbiology · 2026Article
- Analysis and engineering of quorum sensing-based communications between bacteria and fungi.mBio · 2026Review
- Interactions betweenInfection and immunity · 2026Article
- In vitro evaluation of antimicrobial activity of andrographolide against mixed biofilms of Candida albicans and Staphylococcus aureus.BMC complementary medicine and therapies · 2026Article
- Effect of long-lasting antimicrobial surface sprays in real-life environment.BMC infectious diseases · 2026Article
- Update on the role of mycobiome in Gastrointestinal cancers: mechanisms and therapeutic implications.Medical oncology (Northwood, London, England) · 2025Review
- The Pathogenicity Mechanisms ofInternational journal of molecular sciences · 2025Review
- Article
- Understanding Heterogeneity and Tolerance of Dual Candida albicans-Staphylococcus aureus Biofilms to Cold Atmospheric Plasma and Antimicrobial Combinations.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- Strategies for biofilm inhibition: the role of synthetic drug- and nanotechnology-based agents.Archives of microbiology · 2025Review
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Biofilm-associated polymicrobial infections, particularly those involving fungi and bacteria, are responsible for significant morbidity and mortality and tend to be challenging to treat. Candida albicans and Staphylococcus aureus specifically are considered leading opportunistic fungal and bacterial pathogens, respectively, mainly due to their ability to form biofilms on catheters and indwelling medical devices. However, the impact of mixed-species biofilm growth on therapy remains largely understudied. In this study, we investigated the influence of C. albicans secreted cell wall polysaccharides on the response of S. aureus to antibacterial agents in biofilm. Results demonstrated significantly enhanced tolerance for S. aureus to drugs in the presence of C. albicans or its secreted cell wall polysaccharide material. Fluorescence confocal time-lapse microscopy revealed impairment of drug diffusion through the mixed biofilm matrix. Using C. albicans mutant strains with modulated cell wall polysaccharide expression, exogenous supplementation, and enzymatic degradation, the C. albicans-secreted β-1,3-glucan cell wall component was identified as the key matrix constituent providing the bacteria with enhanced drug tolerance. Further, antibody labeling demonstrated rapid coating of the bacteria by the C. albicans matrix material. Importantly, via its effect on the fungal biofilm matrix, the antifungal caspofungin sensitized the bacteria to the drugs. Understanding such symbiotic interactions with clinical relevance between microbial species in biofilms will greatly aid in overcoming the limitations of current therapies and in defining potential new targets for treating polymicrobial infections. IMPORTANCE: The fungus Candida albicans and the bacterium Staphylococcus aureus are important microbial pathogens responsible for the majority of infections in hospitalized patients and are often coisolated from a host. In this study, we demonstrated that when grown together, the fungus provides the bacterium with enhanced tolerance to antimicrobial drugs. This process was mediated by polysaccharides secreted by the fungal cell into the environment. The biofilm matrix formed by these polysaccharides prevented penetration by the drugs and provided the bacteria with protection. Importantly, we show that by inhibiting the production of the fungal polysaccharides, a specific antifungal agent indirectly sensitized the bacteria to antimicrobials. Understanding the therapeutic implications of the interactions between these two diverse microbial species will aid in overcoming the limitations of current therapies and in defining new targets for treating complex polymicrobial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.